The ASX 200 slipped 0.51% to 8,927.7 on Monday as tech and financials dragged, but small caps managed a lift with the Small Ords up 0.57% and the Emerging Companies Index gaining 1.47%.
On Tuesday morning, newsflow is led by Race Oncology opening its first Hong Kong trial site and Nexus Minerals returning standout one-metre gold assays.
Race Oncology activates Hong Kong site
Race Oncology Ltd (ASX:RAC, OTC:RAONF) has activated Queen Mary Hospital in Hong Kong for its Phase 1 RC220 trial in advanced solid tumours. Patient screening is under way, with first dosing expected this month.
A second Hong Kong site is also set to join, complementing ongoing recruitment in Australia. CEO Dr Daniel Tillett said the milestone would accelerate enrolment and expand the eligible patient pool.
Nexus Minerals delivers 30 g/t hit
Nexus Minerals Ltd (ASX:NXM) reported high-grade 1-metre assays from Payns Prospect at its Wallbrook Gold Project, including 1 metre at 30.05 g/t gold within 5 metres at 8.10 g/t. Results confirm continuity of mineralisation and highlight high-grade zones within a broader system.
Nexus has now launched a 6,000-metre RC program across additional regional targets.
Far East Gold doubles targets at Idenburg
Far East Gold Ltd (ASX:FEG) has identified 14 new prospects at its Idenburg Project in Indonesia, taking the total to 29. The satellite imagery study highlights major fault zones across the 95,280-hectare tenement, which lies in a district hosting world-class deposits like Grasberg. CEO Shane Menere said the expanded footprint significantly lifts discovery potential.
Altech secures preliminary €46.7 million grant nod
Altech Batteries Ltd (ASX:ATC, OTC:ALTHF) received conditional approval for a €46.7 million German government grant under the STARK program to support its CERENERGY® solid-state battery project in Saxony.
The grant, covering 30% of project capex, still requires parliamentary budget approval, but represents a key step toward securing non-dilutive funding.